Phentermine's Impact on Treatment in Teens
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Childhood Obesity
In brief
PhITT is a Phase IIb, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of phentermine (16 mg daily) in adolescents aged 12 to \<18 years with obesity. Conducted across approximately 10 sites within the IDeA States Pediatric Clinical Trials Network (ISPCTN), the study aims to enroll up to 240 participants and then randomize up to 198 who meet eligibility criteria, randomized in a 2:1 ratio to phentermine or placebo over a 52-week treatment period, followed by a 2-week withdrawal assessment.
Key facts
- Study ID
- NCT07282340
- Run by
- Russell McCulloh, MD
- People needed
- 240
- Starts
- 2026-06-03
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-08-10
Who can join
Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States (enrolling)
- Children's Mercy Hospital — Kansas City, Missouri, United States (enrolling)
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States (enrolling)
- University of New Mexico Health Sciences Center — Albuquerque, New Mexico, United States (enrolling)
- The University of Oklahoma Health Sciences Children's Hospital — Oklahoma City, Oklahoma, United States (enrolling)
- Prisma Health-Midlands Children's Hospital — Columbia, South Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.